Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
(PORTER Trial)

Recruiting in Palo Alto (17 mi)

+5 other locations

Age: 18+

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Parker Institute for Cancer Immunotherapy

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This study is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of immunotherapy combinations in participants with mCRPC who have received prior secondary androgen receptor signaling inhibitor therapy (eg, abiraterone, enzalutamide, apalutamide).

Research Team

Parker Institute for Cancer Immunotherapy

Principal Investigator

Parker Institute for Cancer Immunotherapy

Eligibility Criteria

Inclusion Criteria

Provide fresh pre-treatment core needle or incisional biopsy of a metastatic tumor lesion not previously irradiated. Fine needle aspiration is not acceptable.

Additionally, if a pre-treatment biopsy is not medically feasible for participants with bone only disease, formalin-fixed paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or at least 10 slides containing unstained, freshly cut, serial sections must be provided.

For all participants, in addition to fresh pre-treatment biopsy, consent for archival tissue is required.

See 7 more